Auri Knowledge
Start a conversation
Request Proposal
Auri Knowledge

Lundbeck Obtains Rights to Research that Targets Immune Checkpoint Pathways in Alzheimer’s

17|06|08//Lundbeck Obtains Rights to Research that Targets Immune Checkpoint Pathways in Alzheimer’s

Source: Alzheimer's News Today. By: Iqra F. Mumal. Lundbeck, a global pharmaceutical company specializing in therapies for neurological disorders, has obtained the rights to IBC’s (ImmunoBrain Checkpoint) groundbreaking research into treatment for Alzheimer’s disease. view more


Start a conversation
Request Proposal
Auri Knowledge
Auri Knowledge